MedPath

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3
Conditions
Fallopian Tube Endometrioid Adenocarcinoma
Ovarian Brenner Tumor
Ovarian Clear Cell Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Stage IIIB Primary Peritoneal Cancer AJCC v7
Stage IIIC Fallopian Tube Cancer AJCC v7
Stage IIIC Primary Peritoneal Cancer AJCC v7
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
Interventions
Other: Clinical Observation
Other: Laboratory Biomarker Analysis
Procedure: Quality-of-Life Assessment
Registration Number
NCT00108745
Lead Sponsor
GOG Foundation
Brief Summary

This randomized phase III trial studies paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating patients with stage III or stage IV ovarian epithelial, peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and polyglutamate paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Paclitaxel and polyglutamate paclitaxel may also stop the growth of ovarian epithelial or peritoneal cancer by blocking blood flow to the tumor. Sometimes, after treatment, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether paclitaxel is more effective than polyglutamate paclitaxel or observation only in treating ovarian epithelial, peritoneal, or fallopian tube cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine whether CT-2103 (polyglutamate paclitaxel) or paclitaxel, administered to women with advanced ovarian, primary peritoneal or fallopian tube cancer who have attained a clinically-defined complete response to primary platinum/taxane-based chemotherapy ("consolidation/maintenance therapy") will reduce the death rate, compared to re-treatment at the time of documented disease progression.

II. To determine if, in this clinical setting, CT-2103 produces a more favorable toxicity profile (with a particular focus on peripheral neuropathy as measured by the Gynecologic Oncology Group \[GOG\] NTX4) and superior quality-of-life (as measured by the Functional Assessment of Cancer Therapy-Ovarian \[FACT-O\]), compared to paclitaxel.

SECONDARY OBJECTIVES:

I. To explore the relationship between expression of several of the angiogenic markers and overall survival or progression-free survival in patients randomized to CT-2103, paclitaxel, or no treatment.

II. To assess the association among the various tissue and serum markers of angiogenesis, and compare the ability of different combinations of these markers to predict patient outcome including overall survival and progression-free survival in patients randomized to CT-2103, paclitaxel, or no treatment.

III. To bank deoxyribonucleic acid (DNA) from whole blood for research and evaluate the association between single nucleotide polymorphisms (SNPs) and measures of clinical outcome including overall survival, progression-free survival and adverse events.

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

ARM I: Patients receive polyglutamate paclitaxel intravenously (IV) over 10-20 minutes on day 1.

ARM II: Patients receive paclitaxel IV over 3 hours on day 1.

ARM III: Patients receive no further anticancer treatment until evidence of disease progression.

In arms I and II, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 10 years.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
1157
Inclusion Criteria
  • Patients with a histologic diagnosis of primary peritoneal carcinoma, or stage III or IV epithelial ovarian or fallopian tube carcinoma, with either optimal (=< 1 cm residual disease) or suboptimal residual disease following initial surgery; all patients must have had appropriate surgery for ovarian, primary peritoneal or fallopian tube carcinoma with appropriate tissue available for histologic evaluation to confirm diagnosis and stage

  • Patients with the following histologic epithelial cell types are eligible:

    • Serous adenocarcinoma
    • Endometrioid adenocarcinoma
    • Mucinous adenocarcinoma
    • Undifferentiated carcinoma
    • Clear cell adenocarcinoma
    • Mixed epithelial carcinoma
    • Transitional cell carcinoma
    • Malignant Brenner tumor
    • Adenocarcinoma not otherwise specified (NOS)
  • Patients must have completed treatment within the past 12 weeks with at least 5 cycles and not more than 8 cycles of a platinum (IV or intraperitoneal [IP]) and paclitaxel or docetaxel-based combination chemotherapy and have no symptoms suggestive of persistent cancer, normal (no evidence of cancer) computed tomography (CT) scan of the abdomen/pelvis and normal cancer antigen 125 (CA-125) following this therapy

    • Patients treated with neo-adjuvant platinum-taxane chemotherapy for a presumptive diagnosis of stage III or IV epithelial ovarian, primary peritoneal or, fallopian tube (by paracentesis, percutaneous biopsy or open biopsy) are eligible provided that they have undergone interval abdominal surgery after at least one but no more than six cycles of standard chemotherapy; such surgery must meet the same criteria as for those undergoing up front surgery, including tissue diagnosis for confirmation of primary tumor site and stage III or IV disease; also, patients must have received at least two cycles after interval abdominal surgery
  • Absolute neutrophil count >= 1,500/ul, equivalent to Common Toxicity Criteria (CTCAE version [v]3.0) grade 1

  • Platelet count >= 100,000/ul

  • Creatinine =< 1.5 times institutional upper limit of normal (ULN), CTCAE v3.0 grade 1

  • Bilirubin =< 1.5 times ULN, (CTCAE v3.0 grade 1)

  • Serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 times ULN (CTCAE v3.0 grade 1)

  • Alkaline phosphatase =< 2.5 times ULN (CTCAE v3.0 grade 1)

  • Neuropathy (sensory and motor) less than or equal to CTCAE v3.0 grade 1

  • Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

  • Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization

  • Patients must complete pre-entry assessments

Exclusion Criteria
  • Patients with a current diagnosis of epithelial ovarian or fallopian tube tumor of low malignant potential (LMP) (Borderline carcinomas) are not eligible; patients with a prior diagnosis of a low malignant potential tumor that was surgically resected and who subsequently develop invasive adenocarcinoma are eligible, provided that they have not received prior chemotherapy for their ovarian LMP tumor

  • Germ cell tumors, sex cord-stromal tumors, carcinosarcomas, mixed mullerian tumors or carcinosarcomas, metastatic carcinomas from other sites to the ovary and low malignant potential tumors including so called micropapillary serous carcinomas are not eligible

  • Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than 3 years prior to registration, and the patient remains free of recurrent or metastatic disease

  • Patients who have received investigational therapies, and/or biological therapies (i.e. Bevacizumab or Erlotinib) for their epithelial ovarian, primary peritoneal or fallopian tube cancers or for any other abdominal or pelvic tumor, are not excluded; however, biologics cannot be continued concurrent with the GOG-012 maintenance treatment (or observation); patients who have received prior chemotherapy for any other abdominal or pelvic tumor (except as noted above) are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than 3 years prior to registration, and that the patient remains free of recurrent or metastatic disease

  • Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met:

    • Stage not greater than I-B
    • Less than 3 mm invasion without vascular or lymphatic invasion
    • No poorly differentiated subtypes, including papillary serous, clear cell, or other Federation of Gynecology and Obstetrics (FIGO) Grade 3 lesions
  • With the exception of non-melanoma skin cancer and other specific malignancies as noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy are excluded

  • Patients with acute hepatitis, or known chronic hepatitis

  • Patients with an active infection that requires antibiotics

  • Patients with ongoing gastrointestinal bleeding requiring blood product support

  • Patients whose circumstances at the time of entry onto the protocol would not permit completion of study or required follow up

  • Patients with unstable angina or those who have had a myocardial infarction within the past six months; patients with evidence of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if their disease has been stable for the past six months

  • Patients are excluded who have had prior therapy with CT-2103

  • Patients with active bleeding or an unexplained prothrombin time (PT) or partial thromboplastin time (PTT) > institutional upper limit normal (ULN)

  • Patients who are pregnant or nursing are excluded; patients who may become pregnant must practice an effective method of birth control

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm I (paclitaxel poliglumex)Quality-of-Life AssessmentPatients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Arm III (observation)Clinical ObservationPatients receive no further anticancer treatment until evidence of disease progression.
Arm I (paclitaxel poliglumex)Laboratory Biomarker AnalysisPatients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Arm III (observation)Quality-of-Life AssessmentPatients receive no further anticancer treatment until evidence of disease progression.
Arm II (paclitaxel)Laboratory Biomarker AnalysisPatients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Arm III (observation)Laboratory Biomarker AnalysisPatients receive no further anticancer treatment until evidence of disease progression.
Arm II (paclitaxel)Quality-of-Life AssessmentPatients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Arm II (paclitaxel)PaclitaxelPatients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Arm I (paclitaxel poliglumex)Paclitaxel PoliglumexPatients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measures
NameTimeMethod
Overall SurvivalAll patients were followed (with physical exams and histories) every three months for the first two years, then every six months for the next three years and then annually for the next five years.

Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact.

Secondary Outcome Measures
NameTimeMethod
Progression-free SurvivalProgression was assessed every 8 weeks for the first 15 months, then every 3 months, up to 14.2 years.

Progression free survival (PFS) was defined as the number of months between study enrollment and the date of first clinical, biochemical, or radiological evidence of progression or death due to any cause. Patients who were alive without progression at the time of analysis were censored on the date of the last tumor assessment.

Patient-Reported Quality of Life (QOL)1. Prior to treatment 2. Prior to cycle 3 3. Prior to cycle 5 4. Prior to cycle 7 5. Prior to cycle 12 6. 12 months post treatment

Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-En TOI is a scale for assessing general QOL of ovarian cancer patients. The FACT-O TOI score ranges 0-100 with a large score suggesting better QOL.

Frequency and Severity of Adverse Effects Assessed by CTCAE v3.0Measured within 6 months of enrollment; through all cycles of chemotherapy and up to 30 days after the last cycle of chemotherapy. Up to 10 cycles of chemotherapy were allowed. Cycles were to be repeated every 3 weeks.

Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy among adverse event terms with at least 4 patients reporting.

Patient-Reported Peripheral Neuropathy Symptoms1. Prior to treatment 2. Prior to cycle 3 3. Prior to cycle 5 4. Prior to cycle 7 5. Prior to cycle 12 6. 12 months post treatment

Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The Ntx score ranges 0-16 with a large score suggesting less peripheral neuropathy symptoms.

Trial Locations

Locations (315)

University of Pennsylvania/Abramson Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Mount Carmel Health Center West

🇺🇸

Columbus, Ohio, United States

MetroHealth Medical Center

🇺🇸

Cleveland, Ohio, United States

West Penn Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

Swedish Medical Center-First Hill

🇺🇸

Seattle, Washington, United States

University of Washington Medical Center - Northwest

🇺🇸

Seattle, Washington, United States

Kaiser Permanente Los Angeles Medical Center

🇺🇸

Los Angeles, California, United States

Mayo Clinic in Arizona

🇺🇸

Scottsdale, Arizona, United States

Beebe Medical Center

🇺🇸

Lewes, Delaware, United States

Highlands Oncology Group PA - Fayetteville

🇺🇸

Fayetteville, Arkansas, United States

Providence Saint Joseph Medical Center/Disney Family Cancer Center

🇺🇸

Burbank, California, United States

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

Southeast Gynecologic Oncology Associates

🇺🇸

Jacksonville, Florida, United States

Eastern Connecticut Hematology and Oncology Associates

🇺🇸

Norwich, Connecticut, United States

Hartford Hospital

🇺🇸

Hartford, Connecticut, United States

UC San Diego Moores Cancer Center

🇺🇸

La Jolla, California, United States

MedStar Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

The Hospital of Central Connecticut

🇺🇸

New Britain, Connecticut, United States

Saint Alphonsus Cancer Care Center-Boise

🇺🇸

Boise, Idaho, United States

Poudre Valley Hospital

🇺🇸

Fort Collins, Colorado, United States

Greater Baltimore Medical Center

🇺🇸

Baltimore, Maryland, United States

Mayo Clinic in Florida

🇺🇸

Jacksonville, Florida, United States

University of Chicago Comprehensive Cancer Center

🇺🇸

Chicago, Illinois, United States

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

Christiana Care - Union Hospital

🇺🇸

Elkton, Maryland, United States

University of Kansas Cancer Center

🇺🇸

Kansas City, Kansas, United States

LSU Health Sciences Center at Shreveport

🇺🇸

Shreveport, Louisiana, United States

South Bend Clinic

🇺🇸

South Bend, Indiana, United States

University of Maryland/Greenebaum Cancer Center

🇺🇸

Baltimore, Maryland, United States

Allegiance Health

🇺🇸

Jackson, Michigan, United States

Michiana Hematology Oncology PC-Plymouth

🇺🇸

Plymouth, Indiana, United States

Woman's Hospital

🇺🇸

Baton Rouge, Louisiana, United States

Bronson Battle Creek

🇺🇸

Battle Creek, Michigan, United States

Memorial Hospital of South Bend

🇺🇸

South Bend, Indiana, United States

CHRISTUS Highland Medical Center

🇺🇸

Shreveport, Louisiana, United States

University of New Mexico Cancer Center

🇺🇸

Albuquerque, New Mexico, United States

State University of New York Downstate Medical Center

🇺🇸

Brooklyn, New York, United States

SSM Health Saint Louis University Hospital

🇺🇸

Saint Louis, Missouri, United States

Bronson Methodist Hospital

🇺🇸

Kalamazoo, Michigan, United States

Borgess Medical Center

🇺🇸

Kalamazoo, Michigan, United States

Kettering Medical Center

🇺🇸

Kettering, Ohio, United States

Novant Health Presbyterian Medical Center

🇺🇸

Charlotte, North Carolina, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

Saint Dominic-Jackson Memorial Hospital

🇺🇸

Jackson, Mississippi, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Mercy Hospital Springfield

🇺🇸

Springfield, Missouri, United States

Mercy Hospital Joplin

🇺🇸

Joplin, Missouri, United States

Jefferson Abington Hospital

🇺🇸

Abington, Pennsylvania, United States

Gynecologic Oncology Network

🇺🇸

Greenville, North Carolina, United States

Rutherford Hospital

🇺🇸

Rutherfordton, North Carolina, United States

Southwest Gynecologic Oncology Associates Inc

🇺🇸

Albuquerque, New Mexico, United States

Northwell Health/Center for Advanced Medicine

🇺🇸

Lake Success, New York, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Singing River Hospital

🇺🇸

Pascagoula, Mississippi, United States

State University of New York Upstate Medical University

🇺🇸

Syracuse, New York, United States

Summa Health System - Akron Campus

🇺🇸

Akron, Ohio, United States

University of Missouri - Ellis Fischel

🇺🇸

Columbia, Missouri, United States

Freeman Health System

🇺🇸

Joplin, Missouri, United States

Long Island Jewish Medical Center

🇺🇸

New Hyde Park, New York, United States

Memorial Medical Center - Las Cruces

🇺🇸

Las Cruces, New Mexico, United States

Mount Sinai Hospital

🇺🇸

New York, New York, United States

Island Gynecologic Oncology

🇺🇸

Brightwaters, New York, United States

Stony Brook University Medical Center

🇺🇸

Stony Brook, New York, United States

Cleveland Clinic Akron General

🇺🇸

Akron, Ohio, United States

Jersey Shore Medical Center

🇺🇸

Neptune, New Jersey, United States

Westchester Medical Center

🇺🇸

Valhalla, New York, United States

Women's Cancer Care Associates LLC

🇺🇸

Albany, New York, United States

Aultman Health Foundation

🇺🇸

Canton, Ohio, United States

Chattanooga's Program in Women's Oncology

🇺🇸

Chattanooga, Tennessee, United States

Ohio State University Comprehensive Cancer Center

🇺🇸

Columbus, Ohio, United States

Riverside Methodist Hospital

🇺🇸

Columbus, Ohio, United States

AnMed Health Cancer Center

🇺🇸

Anderson, South Carolina, United States

Avera Cancer Institute

🇺🇸

Sioux Falls, South Dakota, United States

Chattanooga Gynecological Oncology

🇺🇸

Chattanooga, Tennessee, United States

Oklahoma Cancer Specialists and Research Institute-Tulsa

🇺🇸

Tulsa, Oklahoma, United States

Cone Health Cancer Center

🇺🇸

Greensboro, North Carolina, United States

Geisinger Medical Group

🇺🇸

State College, Pennsylvania, United States

Sanford USD Medical Center - Sioux Falls

🇺🇸

Sioux Falls, South Dakota, United States

Knoxville Gynecologic Cancer Specialists PC

🇺🇸

Knoxville, Tennessee, United States

Geisinger Medical Center

🇺🇸

Danville, Pennsylvania, United States

University of Texas Medical Branch

🇺🇸

Galveston, Texas, United States

Brooke Army Medical Center

🇺🇸

Fort Sam Houston, Texas, United States

Geisinger Wyoming Valley/Henry Cancer Center

🇺🇸

Wilkes-Barre, Pennsylvania, United States

Bay Area Medical Center

🇺🇸

Marinette, Wisconsin, United States

Virginia Oncology Associates - Lake Wright

🇺🇸

Norfolk, Virginia, United States

Northern Virginia Pelvic Surgery Associates

🇺🇸

Annandale, Virginia, United States

Lyndon Baines Johnson General Hospital

🇺🇸

Houston, Texas, United States

Fred Hutchinson Cancer Research Center

🇺🇸

Seattle, Washington, United States

University of Washington Medical Center - Montlake

🇺🇸

Seattle, Washington, United States

Vince Lombardi Cancer Clinic - Slinger

🇺🇸

Slinger, Wisconsin, United States

Franciscan Health Indianapolis

🇺🇸

Indianapolis, Indiana, United States

Women's Cancer Center of Nevada

🇺🇸

Las Vegas, Nevada, United States

University of Cincinnati Cancer Center-UC Medical Center

🇺🇸

Cincinnati, Ohio, United States

University of California San Diego

🇺🇸

San Diego, California, United States

University of Minnesota/Masonic Cancer Center

🇺🇸

Minneapolis, Minnesota, United States

Vanderbilt University/Ingram Cancer Center

🇺🇸

Nashville, Tennessee, United States

LDS Hospital

🇺🇸

Salt Lake City, Utah, United States

Christiana Care Health System-Christiana Hospital

🇺🇸

Newark, Delaware, United States

Associates In Womens Health

🇺🇸

Wichita, Kansas, United States

Saint Mary's Hospital and Regional Medical Center

🇺🇸

Grand Junction, Colorado, United States

Penrose-Saint Francis Healthcare

🇺🇸

Colorado Springs, Colorado, United States

Mercy Hospital

🇺🇸

Coon Rapids, Minnesota, United States

McKee Medical Center

🇺🇸

Loveland, Colorado, United States

Parker Adventist Hospital

🇺🇸

Parker, Colorado, United States

Cancer Center of Kansas - Chanute

🇺🇸

Chanute, Kansas, United States

Cancer Center of Kansas - Parsons

🇺🇸

Parsons, Kansas, United States

Unity Hospital

🇺🇸

Fridley, Minnesota, United States

Cancer Center of Kansas-Independence

🇺🇸

Independence, Kansas, United States

Cancer Center of Kansas-Wichita Medical Arts Tower

🇺🇸

Wichita, Kansas, United States

SCL Health Lutheran Medical Center

🇺🇸

Wheat Ridge, Colorado, United States

Cancer Center of Kansas - Salina

🇺🇸

Salina, Kansas, United States

Wichita NCI Community Oncology Research Program

🇺🇸

Wichita, Kansas, United States

Cancer Center of Kansas - Wichita

🇺🇸

Wichita, Kansas, United States

United Hospital

🇺🇸

Saint Paul, Minnesota, United States

Cancer Center of Kansas - Newton

🇺🇸

Newton, Kansas, United States

Fairview Ridges Hospital

🇺🇸

Burnsville, Minnesota, United States

North Memorial Medical Health Center

🇺🇸

Robbinsdale, Minnesota, United States

Saint Luke's Hospital of Duluth

🇺🇸

Duluth, Minnesota, United States

Metro Minnesota Community Oncology Research Consortium

🇺🇸

Saint Louis Park, Minnesota, United States

Fairview Southdale Hospital

🇺🇸

Edina, Minnesota, United States

Minnesota Oncology Hematology PA-Maplewood

🇺🇸

Maplewood, Minnesota, United States

Littleton Adventist Hospital

🇺🇸

Littleton, Colorado, United States

Cancer Center of Kansas - El Dorado

🇺🇸

El Dorado, Kansas, United States

Cancer Center of Kansas - Pratt

🇺🇸

Pratt, Kansas, United States

Cancer Center of Kansas - Wellington

🇺🇸

Wellington, Kansas, United States

Regions Hospital

🇺🇸

Saint Paul, Minnesota, United States

Ascension Via Christi Hospitals Wichita

🇺🇸

Wichita, Kansas, United States

Minnesota Oncology Hematology PA-Woodbury

🇺🇸

Woodbury, Minnesota, United States

Ridgeview Medical Center

🇺🇸

Waconia, Minnesota, United States

Cancer Center of Kansas - Fort Scott

🇺🇸

Fort Scott, Kansas, United States

Wayne State University/Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

University of Alabama at Birmingham Cancer Center

🇺🇸

Birmingham, Alabama, United States

Rose Medical Center

🇺🇸

Denver, Colorado, United States

Porter Adventist Hospital

🇺🇸

Denver, Colorado, United States

Western States Cancer Research NCORP

🇺🇸

Denver, Colorado, United States

SCL Health Saint Joseph Hospital

🇺🇸

Denver, Colorado, United States

Presbyterian - Saint Lukes Medical Center - Health One

🇺🇸

Denver, Colorado, United States

Providence Portland Medical Center

🇺🇸

Portland, Oregon, United States

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

Tennessee Valley Gynecologic Oncology

🇺🇸

Huntsville, Alabama, United States

Saint Joseph's Hospital and Medical Center

🇺🇸

Phoenix, Arizona, United States

Baptist Health Lexington

🇺🇸

Lexington, Kentucky, United States

Palo Alto Medical Foundation-Gynecologic Oncology

🇺🇸

Mountain View, California, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center

🇺🇸

Orange, California, United States

Rocky Mountain Gynecologic Oncology PC

🇺🇸

Englewood, Colorado, United States

North Colorado Medical Center

🇺🇸

Greeley, Colorado, United States

University of Connecticut

🇺🇸

Farmington, Connecticut, United States

Smilow Cancer Hospital Care Center at Saint Francis

🇺🇸

Hartford, Connecticut, United States

Holy Cross Hospital

🇺🇸

Fort Lauderdale, Florida, United States

Florida Gynecologic Oncology

🇺🇸

Fort Myers, Florida, United States

Women's Cancer Associates

🇺🇸

Saint Petersburg, Florida, United States

Sarasota Memorial Hospital

🇺🇸

Sarasota, Florida, United States

University of Illinois

🇺🇸

Chicago, Illinois, United States

Advocate Lutheran General Hospital

🇺🇸

Park Ridge, Illinois, United States

Memorial Medical Center

🇺🇸

Springfield, Illinois, United States

Michiana Hematology Oncology PC-South Bend

🇺🇸

South Bend, Indiana, United States

Northern Indiana Cancer Research Consortium

🇺🇸

South Bend, Indiana, United States

Michiana Hematology Oncology PC-Westville

🇺🇸

Westville, Indiana, United States

Cancer Center of Kansas - Dodge City

🇺🇸

Dodge City, Kansas, United States

Cancer Center of Kansas-Kingman

🇺🇸

Kingman, Kansas, United States

Saint Luke's South Hospital

🇺🇸

Overland Park, Kansas, United States

Kansas City NCI Community Oncology Research Program

🇺🇸

Prairie Village, Kansas, United States

Cancer Center of Kansas - Winfield

🇺🇸

Winfield, Kansas, United States

Massachusetts General Hospital Cancer Center

🇺🇸

Boston, Massachusetts, United States

UMass Memorial Medical Center - Memorial Division

🇺🇸

Worcester, Massachusetts, United States

Ascension Saint John Hospital

🇺🇸

Detroit, Michigan, United States

Mercy Health Saint Mary's

🇺🇸

Grand Rapids, Michigan, United States

Spectrum Health at Butterworth Campus

🇺🇸

Grand Rapids, Michigan, United States

Mercy Health Mercy Campus

🇺🇸

Muskegon, Michigan, United States

Lakeland Hospital Niles

🇺🇸

Niles, Michigan, United States

Lake Huron Medical Center

🇺🇸

Port Huron, Michigan, United States

Abbott-Northwestern Hospital

🇺🇸

Minneapolis, Minnesota, United States

Park Nicollet Clinic - Saint Louis Park

🇺🇸

Saint Louis Park, Minnesota, United States

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

Saint Luke's East - Lee's Summit

🇺🇸

Lee's Summit, Missouri, United States

Mercy Hospital Saint Louis

🇺🇸

Saint Louis, Missouri, United States

Center of Hope at Renown Medical Center

🇺🇸

Reno, Nevada, United States

Cooper Hospital University Medical Center

🇺🇸

Camden, New Jersey, United States

Virtua Memorial

🇺🇸

Mount Holly, New Jersey, United States

Queens Hospital Center

🇺🇸

Jamaica, New York, United States

North Shore University Hospital

🇺🇸

Manhasset, New York, United States

Laura and Isaac Perlmutter Cancer Center at NYU Langone

🇺🇸

New York, New York, United States

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

🇺🇸

New York, New York, United States

Cone Health Cancer Center at Alamance Regional

🇺🇸

Burlington, North Carolina, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

New Hanover Regional Medical Center/Zimmer Cancer Center

🇺🇸

Wilmington, North Carolina, United States

Cleveland Clinic Cancer Center/Fairview Hospital

🇺🇸

Cleveland, Ohio, United States

Compass Oncology Rose Quarter

🇺🇸

Portland, Oregon, United States

Saint Luke's University Hospital-Bethlehem Campus

🇺🇸

Bethlehem, Pennsylvania, United States

Geisinger Medical Center-Cancer Center Hazleton

🇺🇸

Hazleton, Pennsylvania, United States

Women and Infants Hospital

🇺🇸

Providence, Rhode Island, United States

Baptist Memorial Hospital and Cancer Center-Memphis

🇺🇸

Memphis, Tennessee, United States

M D Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Seattle Cancer Care Alliance

🇺🇸

Seattle, Washington, United States

MultiCare Tacoma General Hospital

🇺🇸

Tacoma, Washington, United States

Green Bay Oncology Limited at Saint Mary's Hospital

🇺🇸

Green Bay, Wisconsin, United States

University of Colorado Hospital

🇺🇸

Aurora, Colorado, United States

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

Walter Reed National Military Medical Center

🇺🇸

Bethesda, Maryland, United States

Nebraska Methodist Hospital

🇺🇸

Omaha, Nebraska, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Aurora Saint Luke's Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

CoxHealth South Hospital

🇺🇸

Springfield, Missouri, United States

Case Western Reserve University

🇺🇸

Cleveland, Ohio, United States

Pennsylvania Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Miami Valley Hospital

🇺🇸

Dayton, Ohio, United States

UH Seidman Cancer Center at Lake Health Mentor Campus

🇺🇸

Mentor, Ohio, United States

Penn State Milton S Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Reading Hospital

🇺🇸

West Reading, Pennsylvania, United States

UT Southwestern/Simmons Cancer Center-Dallas

🇺🇸

Dallas, Texas, United States

The Don and Sybil Harrington Cancer Center

🇺🇸

Amarillo, Texas, United States

Houston Methodist Hospital

🇺🇸

Houston, Texas, United States

Virginia Mason Medical Center

🇺🇸

Seattle, Washington, United States

University of Virginia Cancer Center

🇺🇸

Charlottesville, Virginia, United States

Skagit Valley Hospital Regional Cancer Care Center

🇺🇸

Mount Vernon, Washington, United States

Bon Secours Mary Immaculate Hospital

🇺🇸

Newport News, Virginia, United States

Carilion Clinic Gynecological Oncology

🇺🇸

Roanoke, Virginia, United States

Harrison HealthPartners Hematology and Oncology-Bremerton

🇺🇸

Bremerton, Washington, United States

Pacific Gynecology Specialists

🇺🇸

Seattle, Washington, United States

Providence Saint Mary Regional Cancer Center

🇺🇸

Walla Walla, Washington, United States

Long Beach Memorial Medical Center-Todd Cancer Institute

🇺🇸

Long Beach, California, United States

Cedars Sinai Medical Center

🇺🇸

Los Angeles, California, United States

UCLA / Jonsson Comprehensive Cancer Center

🇺🇸

Los Angeles, California, United States

UCSF Medical Center-Mount Zion

🇺🇸

San Francisco, California, United States

John B Amos Cancer Center

🇺🇸

Columbus, Georgia, United States

Morton Plant Hospital

🇺🇸

Clearwater, Florida, United States

Northwestern Medicine Cancer Center Warrenville

🇺🇸

Warrenville, Illinois, United States

Sudarshan K Sharma MD Limited-Gynecologic Oncology

🇺🇸

Hinsdale, Illinois, United States

Northeast Georgia Medical Center-Gainesville

🇺🇸

Gainesville, Georgia, United States

Memorial Health University Medical Center

🇺🇸

Savannah, Georgia, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

Central Georgia Gynecologic Oncology

🇺🇸

Macon, Georgia, United States

Decatur Memorial Hospital

🇺🇸

Decatur, Illinois, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

Michiana Hematology Oncology PC-Elkhart

🇺🇸

Elkhart, Indiana, United States

Indiana University/Melvin and Bren Simon Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Saint Vincent Hospital and Health Care Center

🇺🇸

Indianapolis, Indiana, United States

Elkhart General Hospital

🇺🇸

Elkhart, Indiana, United States

Community Howard Regional Health

🇺🇸

Kokomo, Indiana, United States

IU Health La Porte Hospital

🇺🇸

La Porte, Indiana, United States

Michiana Hematology Oncology PC-Mishawaka

🇺🇸

Mishawaka, Indiana, United States

The Community Hospital

🇺🇸

Munster, Indiana, United States

University of Iowa/Holden Comprehensive Cancer Center

🇺🇸

Iowa City, Iowa, United States

New York Hospital Medical Center of Queens

🇺🇸

Fresh Meadows, New York, United States

Hope Women's Cancer Centers-Asheville

🇺🇸

Asheville, North Carolina, United States

Sutter Medical Center Sacramento

🇺🇸

Sacramento, California, United States

University of California Davis Comprehensive Cancer Center

🇺🇸

Sacramento, California, United States

Michigan Cancer Research Consortium NCORP

🇺🇸

Ann Arbor, Michigan, United States

Saint Joseph Mercy Hospital

🇺🇸

Ann Arbor, Michigan, United States

University of Michigan Comprehensive Cancer Center

🇺🇸

Ann Arbor, Michigan, United States

Southeast Clinical Oncology Research Consortium NCORP

🇺🇸

Winston-Salem, North Carolina, United States

Boulder Community Hospital

🇺🇸

Boulder, Colorado, United States

Emory University Hospital/Winship Cancer Institute

🇺🇸

Atlanta, Georgia, United States

Hillcrest Hospital Cancer Center

🇺🇸

Mayfield Heights, Ohio, United States

Saint Joseph Regional Medical Center-Mishawaka

🇺🇸

Mishawaka, Indiana, United States

University of Pittsburgh Cancer Institute (UPCI)

🇺🇸

Pittsburgh, Pennsylvania, United States

UPMC-Magee Womens Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

Cancer Care Northwest - Spokane South

🇺🇸

Spokane, Washington, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

AdventHealth Orlando

🇺🇸

Orlando, Florida, United States

Orlando Health Cancer Institute

🇺🇸

Orlando, Florida, United States

Norton Hospital Pavilion and Medical Campus

🇺🇸

Louisville, Kentucky, United States

The James Graham Brown Cancer Center at University of Louisville

🇺🇸

Louisville, Kentucky, United States

Saint Luke's Hospital of Kansas City

🇺🇸

Kansas City, Missouri, United States

Research Medical Center

🇺🇸

Kansas City, Missouri, United States

UNC Lineberger Comprehensive Cancer Center

🇺🇸

Chapel Hill, North Carolina, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Yale University

🇺🇸

New Haven, Connecticut, United States

Munson Medical Center

🇺🇸

Traverse City, Michigan, United States

Aurora West Allis Medical Center

🇺🇸

West Allis, Wisconsin, United States

William Beaumont Hospital-Royal Oak

🇺🇸

Royal Oak, Michigan, United States

Sparrow Hospital

🇺🇸

Lansing, Michigan, United States

ProHealth Waukesha Memorial Hospital

🇺🇸

Waukesha, Wisconsin, United States

Ascension Saint Mary's Hospital

🇺🇸

Saginaw, Michigan, United States

Morristown Medical Center

🇺🇸

Morristown, New Jersey, United States

Vince Lombardi Cancer Clinic-Sheboygan

🇺🇸

Sheboygan, Wisconsin, United States

West Michigan Cancer Center

🇺🇸

Kalamazoo, Michigan, United States

Wake Forest University Health Sciences

🇺🇸

Winston-Salem, North Carolina, United States

Cancer Research Consortium of West Michigan NCORP

🇺🇸

Grand Rapids, Michigan, United States

Spectrum Health Big Rapids Hospital

🇺🇸

Big Rapids, Michigan, United States

Lakeland Medical Center Saint Joseph

🇺🇸

Saint Joseph, Michigan, United States

Metro Health Hospital

🇺🇸

Wyoming, Michigan, United States

NYU Winthrop Hospital

🇺🇸

Mineola, New York, United States

Sibley Memorial Hospital

🇺🇸

Washington, District of Columbia, United States

MedStar Franklin Square Medical Center/Weinberg Cancer Institute

🇺🇸

Baltimore, Maryland, United States

Saint Joseph Mercy Oakland

🇺🇸

Pontiac, Michigan, United States

Dartmouth Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Hurley Medical Center

🇺🇸

Flint, Michigan, United States

Black Hills Obstetrics and Gynecology

🇺🇸

Rapid City, South Dakota, United States

University of Vermont Medical Center

🇺🇸

Burlington, Vermont, United States

Aurora Cancer Care-Grafton

🇺🇸

Grafton, Wisconsin, United States

Gundersen Lutheran Medical Center

🇺🇸

La Crosse, Wisconsin, United States

Holy Family Memorial Hospital

🇺🇸

Manitowoc, Wisconsin, United States

Green Bay Oncology at Saint Vincent Hospital

🇺🇸

Green Bay, Wisconsin, United States

Saint Vincent Hospital Cancer Center Green Bay

🇺🇸

Green Bay, Wisconsin, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

Iowa Methodist Medical Center

🇺🇸

Des Moines, Iowa, United States

Iowa-Wide Oncology Research Coalition NCORP

🇺🇸

Des Moines, Iowa, United States

Mercy Medical Center - Des Moines

🇺🇸

Des Moines, Iowa, United States

Iowa Lutheran Hospital

🇺🇸

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates-Des Moines

🇺🇸

Des Moines, Iowa, United States

Medical Oncology and Hematology Associates-Laurel

🇺🇸

Des Moines, Iowa, United States

University of Kentucky/Markey Cancer Center

🇺🇸

Lexington, Kentucky, United States

Tulane University Health Sciences Center

🇺🇸

New Orleans, Louisiana, United States

Ochsner Medical Center Jefferson

🇺🇸

New Orleans, Louisiana, United States

Dell Seton Medical Center at The University of Texas

🇺🇸

Austin, Texas, United States

Virginia Commonwealth University/Massey Cancer Center

🇺🇸

Richmond, Virginia, United States

University of Wisconsin Hospital and Clinics

🇺🇸

Madison, Wisconsin, United States

Baystate Medical Center

🇺🇸

Springfield, Massachusetts, United States

Saint Mary Mercy Hospital

🇺🇸

Livonia, Michigan, United States

Spectrum Health Reed City Hospital

🇺🇸

Reed City, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath